Pemvidutide and the RECLAIM trial
Pemvidutide is being studied for alcohol use disorder as well as liver disease. On November 5, Altimmune announced that RECLAIM results would be presented at AASLD’s November 9 meeting session. The announcement renews attention to findings first reported in July; it is not an FDA approval. 1
Why is this peptide being studied beyond weight loss?
Pemvidutide is an investigational peptide that activates glucagon and GLP-1 receptors. The current announcement concerns alcohol use disorder, rather than a weight-management approval. Keeping the indication explicit helps avoid treating every development involving GLP-1 biology as the same clinical story. 1
As of November 6, the presentation remains forthcoming. Any account should distinguish its scheduled date from the older numerical results already available. 1
Who took part in RECLAIM, and what was measured?
The registered Phase 2 study enrolled 100 adults with alcohol use disorder and overweight or obesity. It compared pemvidutide with placebo over 24 weeks. The main measure was the change in average weekly heavy drinking days, evaluated over weeks 21–24 against baseline. 2
The registry defines a heavy drinking day using different thresholds for men and women and records alcohol consumption through the Timeline Followback method. It also lists additional drinking and biomarker outcomes. These measures describe trial endpoints, not instructions about an acceptable amount of alcohol. 2
What did the company report?
Altimmune’s July 28 release reported reductions of 4.20 versus 2.75 heavy drinking days per week, a model-estimated between-group difference of 1.45 days. The primary comparison had a reported p-value of 0.0014. These are sponsor-reported topline results. 3
| Reported measure | Pemvidutide | Placebo |
|---|---|---|
| Weekly heavy drinking days: change from baseline | −4.20 | −2.75 |
| Participants with zero heavy drinking days in weeks 21–24 | 42.2% | 17.4% |
What does that result leave unanswered?
A decrease from baseline includes changes observed in the placebo group as well as the active-treatment group. That is why the difference between groups matters. Similarly, zero heavy drinking days is not the same endpoint as complete abstinence: the labels should not be swapped when reporting the result.
The release also reports nausea in 44% of pemvidutide participants versus 24% with placebo, and drug-related adverse events causing treatment discontinuation in 10% versus 0%. One serious hyponatremia event was considered possibly treatment-related. These findings belong alongside the efficacy numbers. 3
What comes next for the US program?
Altimmune has scheduled an end-of-Phase 2 FDA meeting in December to discuss AUD development. That discussion and the conference presentation are milestones, not evidence of Phase 3 success or approval. 1
The next report should make the analysis population, missing-data handling, durability and adverse-event comparisons easier to examine. Readers should also keep AUD outcomes separate from results in MASH or alcohol-associated liver disease; a shared molecule does not make those populations and endpoints interchangeable.
Scope for European readers
This is a dated account of the research or policy described in the linked sources. The stated jurisdiction, study product and population matter. A US or UK announcement does not establish authorisation or availability across Europe. Nothing in this report establishes results for an EPS catalogue material. Read the research-use statement for the storefront's scope.